Abstract：
OBJECTIVE: Abdominal Aortic Aneurysms (AAA) growth remains a process not fully understood. The objective of this study was to analyze risk factors associated with changes in AAA diameter in a Mexican cohort.
METHODS: An observational study in which we analyzed the entirely of patients in which an AAA was reported in a Computed Tomography (CT) study from 2014 to 2021 who had a follow-up CT. We divided them by groups depending on the diagnosis of type 2 diabetic mellitus and pharmacological history (diabetic vs non-diabetic, metformin vs non-metformin intake and statin vs non-statin intake). We compared pre and post follow-up AAA diameters using paired t-tests. A multivariate analysis was performed in order to identify independent variables associated with an increased growth rate. Statistical analysis was performed on Stata 17.
RESULTS: During the studied period 72 (39.77%) patients had a follow-up CT. Mean age was 75 years (±9.05) and 52 (72.22%) were men. When comparing infra-renal largest diameter through time based on metformin intake, a significant difference was found only in the metformin non-intake group (42.05 ± 12.54 vs45.34 ± 12.06 [P = 0.02]), in contrast the metformin intake group measures were non-significantly different (36.13 ± 7.04 vs 37.00 ± 4.51; P = 0.57) through follow-up. In the multivariate analysis AAA largest diameter at diagnosis correlated with significantly increased growth rate (coeff = 0.06, P < 0.05).
CONCLUSIONS: AAA diameters appear to change through time in a non-linear pattern influenced by different epidemiological and clinical factors. Metformin intake appears to promote a stability in AAA diameter growth in our studied population.
METHODS: An observational study in which we analyzed the entirely of patients in which an AAA was reported in a Computed Tomography (CT) study from 2014 to 2021 who had a follow-up CT. We divided them by groups depending on the diagnosis of type 2 diabetic mellitus and pharmacological history (diabetic vs non-diabetic, metformin vs non-metformin intake and statin vs non-statin intake). We compared pre and post follow-up AAA diameters using paired t-tests. A multivariate analysis was performed in order to identify independent variables associated with an increased growth rate. Statistical analysis was performed on Stata 17.
RESULTS: During the studied period 72 (39.77%) patients had a follow-up CT. Mean age was 75 years (±9.05) and 52 (72.22%) were men. When comparing infra-renal largest diameter through time based on metformin intake, a significant difference was found only in the metformin non-intake group (42.05 ± 12.54 vs45.34 ± 12.06 [P = 0.02]), in contrast the metformin intake group measures were non-significantly different (36.13 ± 7.04 vs 37.00 ± 4.51; P = 0.57) through follow-up. In the multivariate analysis AAA largest diameter at diagnosis correlated with significantly increased growth rate (coeff = 0.06, P < 0.05).
CONCLUSIONS: AAA diameters appear to change through time in a non-linear pattern influenced by different epidemiological and clinical factors. Metformin intake appears to promote a stability in AAA diameter growth in our studied population.
摘要：
目的：腹主动脉瘤（AAA）的生长仍是一个尚未完全了解的过程。这项研究的目的是分析墨西哥队列中与AAA直径变化相关的危险因素。
方法：一项观察性研究，我们分析了2014年至2021年在计算机断层扫描（CT）研究中报告AAA并进行了随访CT的患者的全部情况。我们根据2型糖尿病的诊断和药理学史（糖尿病与非糖尿病，二甲双胍与非二甲双胍摄入量和他汀类药物与非他汀类药物摄入量)。我们使用配对t检验比较了随访前后的AAA直径。进行多变量分析以鉴定与增加的生长速率相关的独立变量。对Stata17进行统计分析。
结果：在研究期间，72例（39.77%）患者进行了CT随访。平均年龄为75岁（±9.05），男性为52岁（72.22％）。当根据二甲双胍摄入量比较肾下最大直径时，仅在二甲双胍非摄入组中发现显着差异（42.05±12.54vs45.34±12.06[P=0.02]），相反，通过随访，二甲双胍摄入组的测量值无明显差异（36.13±7.04vs37.00±4.51；P=0.57）。在多变量分析中，诊断时AAA最大直径与生长速率显着增加相关（coeff=0.06，P<0.05）。
结论：AAA直径在不同的流行病学和临床因素的影响下呈非线性随时间变化。在我们研究的人群中，二甲双胍的摄入似乎促进了AAA直径增长的稳定性。
方法：一项观察性研究，我们分析了2014年至2021年在计算机断层扫描（CT）研究中报告AAA并进行了随访CT的患者的全部情况。我们根据2型糖尿病的诊断和药理学史（糖尿病与非糖尿病，二甲双胍与非二甲双胍摄入量和他汀类药物与非他汀类药物摄入量)。我们使用配对t检验比较了随访前后的AAA直径。进行多变量分析以鉴定与增加的生长速率相关的独立变量。对Stata17进行统计分析。
结果：在研究期间，72例（39.77%）患者进行了CT随访。平均年龄为75岁（±9.05），男性为52岁（72.22％）。当根据二甲双胍摄入量比较肾下最大直径时，仅在二甲双胍非摄入组中发现显着差异（42.05±12.54vs45.34±12.06[P=0.02]），相反，通过随访，二甲双胍摄入组的测量值无明显差异（36.13±7.04vs37.00±4.51；P=0.57）。在多变量分析中，诊断时AAA最大直径与生长速率显着增加相关（coeff=0.06，P<0.05）。
结论：AAA直径在不同的流行病学和临床因素的影响下呈非线性随时间变化。在我们研究的人群中，二甲双胍的摄入似乎促进了AAA直径增长的稳定性。
